c‐erbB‐3 protein expression in human breast cancer: comparison with other tumour variables and survival

Abstract
C‐erbB‐3 protein expression was investigated immunohistochemically in a series of 97 malignant breast tumours using the monoclonal antibody RTJ1. Twenty‐eight cases (28.8%) showed c‐erbB‐3 overexpression, 31 cases (32%) showed normal levels of c‐erbB‐3 and 38 cases (39.2%) were c‐erbB‐3 negative. c‐erbB‐3 overexpression was positively but not significantly related to negative lymph node status and survival over a 10‐year follow‐up period.